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Background: The principal human estrogen, 17p-estra-
diol, is a potent stimulator of certain endocrine-depen-
dent forms of breast cancer. Because human estrogenic
173-hydroxysteroid dehydrogenase (type I 173-HSD)
catalyzes the last step in the biosynthesis of 17[3-estradiol
from the less potent estrogen, estrone, it is an attractive
target for the design of inhibitors of estrogen production
and tumor growth. This human enzyme shares less than
15% sequence identity with a bacterial 3ao,203-HSD, for
which the three-dimensional structure is known. The
amino acid sequence of 173-HSD also differs from that of
bacterial 3ot,203-HSD by two insertions (of 11 and 14
residues) and 52 additional residues at the C terminus.
Results: The 2.20 A resolution structure of type I
173-HSD, the first mammalian steroidogenic enzyme
studied by X-ray crystallographic techniques, reveals a
fold characteristic of the short-chain dehydrogenases. The
active site contains a Tyr-X-X-X-Lys sequence (where X
is any amino acid) and a serine residue, features that are
conserved in short-chain steroid dehydrogenases. The
structure also contains three ot-helices and a helix-turn-
helix motif, not observed in short-chain dehydrogenase
structures reported previously. No cofactor density could
be located.
Conclusions: The helices present in 17P3-HSD that were
not in the two previous short-chain dehydrogenase struc-
tures are located at one end of the substrate-binding cleft
away from the catalytic triad. These helices restrict access
to the active site and appear to influence substrate speci-
ficity. Modeling the position of estradiol in the active site
suggests that a histidine side chain may play a critical role
in substrate recognition. One or more of these helices
may also be involved in the reported association of the
enzyme with membranes. A model for steroid and cofac-
tor binding as well as for the estrone to estradiol transition
state is proposed. The structure of the active site provides
a rational basis for designing more specific inhibitors of
this breast cancer associated enzyme.
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Introduction
Steroids, including 171-estradiol and androst-5-ene-
3P,1713-diol (A5-diol), are potent stimulators of breast
cancer cell growth [1-6]. Because human estrogenic
17,3-hydroxysteroid dehydrogenase (type I 173-HSD)
catalyzes the last step in the biosynthesis of the most
active estrogen, 173-estradiol, from estrone [7-9], it is an
attractive target for the design of inhibitors of estrogen
production and tumor growth [10]. The gene encoding
type I human 171-HSD and a tandem pseudogene are
located on the q11-q12 region of chromosome 17 [9,11],
near the BRCA1 gene associated with hereditary breast
and ovarian cancers [12].
Estrogenic 17P-HSD was purified from human placenta
[9], where it is present in soluble and membrane-associ-
ated forms. We have expressed type I 17,3-HSD cDNA
in insect cells, where it is also distributed between soluble
and membrane fractions [13]. The fact that salt extraction
of 17P-HSD in aqueous medium requires the addition of
sodium cholate, and crystallization requires the presence
of octyl glucoside detergent [14,15], indicates the hydro-
phobic nature of the surface residues and the affinity of
the'enzyme for cell membranes.
After purification to homogeneity [9,14,15], the homo-
dimeric nature of 1713-HSD was demonstrated [15].
Mechanisms of enzyme action and the composition of
the active site have been probed by biochemical methods
[16-19]. Sequence alignment analyses and homology
studies [20-23] revealed that 1713-HSD blongs to the
short-chain dehydrogenase superfamily, arid has a charac-
teristic Tyr-X-X-X-Lys sequence of residues at the active
site. The invariant tyrosine and lysine residues have been
shown to be catalytically important by site-directed
mutagenesis [24-26] and are found at the active sites of
bacterial 3ot,2013-HSD [21,27] and rat liver dihydropteri-
dine reductase (DHPR) [28], two members of the family
whose three-dimensional structures have been reported.
Here we report the three-dimensional structure of
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human type I 170-HSD, describe the active site of the
enzyme in detail and propose a binding mode for the
steroid and a model of the transition state of the estrone
to estradiol reaction.
Results and discussion
Description of the structure
The structure of type I 17P-HSD from human placenta
was determined at 2.20 A resolution by a combination of
isomorphous heavy-atom derivative and molecular
replacement techniques. The structure of bacterial
3o,20P-HSD was used as the search model. Tables 1-4
summarize data collection, heavy-atom phasing, phase
combination and refinement results, respectively. The
refinement was also carried out with a 2.5 A data set col-
lected on a crystal of the recombinant enzyme, isomor-
phous to that of the native enzyme. These two refined
structures are identical.
Forty-three residues at the C terminus of the protein
(285-327) could not be located and residues 192-199
had very weak density. The amino acid side chains for
the rest of the protein were clearly defined in
electron-density maps and the agreement between the
cDNA-derived sequence [9] and the electron density of
the amino acid side chains was excellent. The ribbon
diagram of a monomer of 17-HSD (Fig. la) reveals the
same arrangement of [-sheet and ot-helices as has been
observed in structures of bacterial 3ot,20P-HSD [21,27]
and rat liver DHPR [28]. There are, however, some
structural features in 1713-HSD that are not observed in
the other two enzymes. There are 327 amino acid
residues in 17,3-HSD [9], compared with 255 and 240 in
3oL,20P-HSD and DHPR, respectively. Of the 76 addi-
tional residues in 17[-HSD (the N terminus of
17[g-HSD is four residues shorter than in 3ot,20-HSD),
52 are at the C terminus and 14 are inserted at position
200 (based on 3oa,20P3-HSD numbering) and reside near
the active site. Together, these additions alter the topog-
raphy of one end of the active site of 17P-HSD relative
to 3ot,20P-HSD and DHPR.
The core of the structure is the seven-stranded parallel
3-sheet (A to G), surrounded by six parallel a-helices
(aB to otG), three on each side of the 3-sheet (Fig. la,b).
Table 1. Summary of data collection for native and derivative crystals.
Crystal type Soaking conditions No. of Maximum Total Unique F2/a(F2) Completeness (%) R(F2) R(F) %
(no. of sites) crystals resolution data data last 0.10 A % native-to-
used (A) shell merge derivative
Native:
purified from
placenta
1.17[3-HSD3 ---- 1 2.20 27407 12973 2.97 76 4.93
2. 17P-HSD5 1 2.20 16553 12644 2.00 73 6.58
3. Combined 2 2.20 43 960 14079 2.50 81 6.44
Native:
recombinant
1. 17-HSD9 ---- 1 2.52 28026 10367 2.01 90 8.59 ----
Hg4:HgCI 2 0.2 mM, 27 days; 1 3.00 13539 5429 2.80 80 7.26 10.6(1 major, 1 minor)
HglO:HgCI2 0.2 mM, 41 days; 1 3.00 6612 4781 3.29 67 8.75 21.1(1 major, 1 minor)
Hgl 1 :HgCI 2 0.2 mM, 42 days; 1 3.00 5935 3968 6.12 56 5.45 15.7(1 major, 1 minor)
Table 2. Isomorphous replacement phasing statistics.
Derivative Reflections Highest R-Centric* Phasing Phasing powert
phased resolution powert in the last shell
Hg4:HgCI 2 3825 3.2 A 0.71 1.35 1.18
HglO:HgCI 2 3568 3.2 A 0.62 1.63 1.58
Hgl 1:HgCI 2 3086 3.2 A 0.57 1.69 1.58
*R-Centric is R-Cullis for centric reflections and is defined as R=:111FpHI+Fpll-IfHll/IIFpH+ IFpII, where P and H refer to parent and
heavy-atom derivative data sets respectively and IFI is the measured structure amplitudes. tPhasing power is defined as fH rms/lack
of closure.
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Table 3. Statistics from phase combination.
Resolution (A) 3.20
Number of reflections 4072
SIR* figure of merit (FOM) 0.49
Combined FOM (model and SIR) 0.80
Correlation coefficient 0.97
Rinverse 0.23
*SIR: single isomorphous replacement.
Table 4. Refinement statistics.
Protein source
Isolated from Recombinant
human placenta
Protein atoms in model
(284 out of 327 residues) 2179 2179
Solvent atoms: water 49 46
Resolution range 8.00-2.20 A 8.00-2.52 A
Unique data used (F>oF) 13474 9641
R-factor 0.185 0.172
Free R-factor 0.229 0.228
Rms deviation:
Bond distance (A) 0.010 0.011
Bond angle () 1.68 1.77
Dihedral angle () 23.55 24.24
Planarity () 1.46 1.52
Ramachandran plot statistics:
% residues out of a total of
234 non-glycine and non-
proline residues in most
favored regions 91.5 90.0
% residues in disallowed
regions 0.0 0.0
Estimated random positional
error (A) from Luzzati plot 0.20-0.25 0.25
The basic fold of the segment PA to F is a doubly
wound a/3 motif, with alternating 3-strands and
a-helices. Whereas the PA to 3F segment is the classic
'Rossmann fold', associated with nicotinamide adenine
dinucleotide binding, the OD to f3G segment, in addition
to being partly in the Rossmann fold, governs quaternary
association and substrate binding [21]. In 3ao,203-HSD
and DHPR [21,28], the cofactor and the substrate-bind-
ing sites are combined in a single domain. In 17P-HSD, a
long helix, oaG' (Figs 1,2), is inserted in the loop between
3F and aoG. Two additional helices, aG" (residues
200-206) and aG' (residues 209-229) create a helix-
turn-helix (HTH) motif preceding the helix aG. Helices
aH' (residues 260-266) and aH (residues 273-284) form
another HTH motif that is not present in 3t,2003-HSD
or DHPR. Together, these segments of the polypeptide
chain (residues 190-229 and residues 259-284), contain-
ing helices aG", aG', aH' and aH, form one end of the
'substrate-binding domain' (Fig. 3). Mass spectrometric
determination of the molecular weight of the crystalline
enzyme indicates that all 327 residues are present in the
crystal (S-X Lin, unpublished data). However, the ao-car-
bon chain cannot be traced beyond residue 284 because
the electron density is so diffuse. The missing 43-residue
C-terminal segment is rich in alanine, glycine and pro-
line residues, and has a repeating Ala-Gly sequence
which may account for its lack of secondary structure
and/or high thermal motion.
Monomers related by the crystallographic two-fold axis
form the closest dimeric association in the crystal
(Fig. 4), an association analogous to the Q-axis dimer-
ization in tetrameric 3a,20f3-HSD [21] and dimeric
DHPR [28]. At the dimer interface, helices otE and oaF
from each monomer form a four-helix bundle. The sec-
ond interface in 3a,2013-HSD, the P-axis interface,
which allows antiparallel association of the two PG
strands and the two aG helices about a non-crystallo-
graphic two-fold axis, is accessible in the crystal structure
of 173-HSD, but not used. This contrasts with the
DHPR structure, where an eighth P-strand, H,
antiparallel to IPG exists so that no P-axis interface analo-
gous to that in 3,2013-HSD could be formed. If, as has
been reported [15], 1713-HSD is active as a dimer, it is
likely to take the form illustrated in Figure 4. A postu-
lated tetrameric assembly of 1713-HSD monomers [29]
could be achieved through formation of a similar P-axis-
type association of two of the dimers shown in Figure 4.
Architecture of the active site
The catalytic site comprises a cofactor-binding cleft and a
steroid-binding cleft. Although 1 mM NADP+ was pre-
sent in the crystallization medium, density corresponding
to the cofactor could not be reliably identified. The
model of the cofactor position in the binding cleft of
1713-HSD was derived from a superposition of the struc-
tures of 173-HSD and a complex of 3Oa,2013-HSD with
NAD + using a least-squares fitting procedure with 20 Cot
atoms that were found to have highly similar relative posi-
tions in the two enzymes (Table 5). These Caot atoms
(including those of the catalytic triads) were within 1 A of
one another in the initial fitting. The average root mean
square (rms) deviation for these atoms was 0.7 A. Figure 5
is a stereodiagram of the superimposed Caot chains of
171-HSD and the 3ot,2013-HSD-NAD + complex. Dif-
ferences may exist between the binding modes for
NAD(H) to 3ao,201-HSD and for NADP+(H) to
173-HSD. Asp37 in 3a,203-HSD, which forms hydro-
gen bonds to the 2'- and 3'-hydroxyls of the ribose at the
adenine end, is replaced by Leu36 in 1713-HSD. The
analogous residue is a valine in glutathione reductase,
another NADP+-specific enzyme with a Rossmann fold.
From a comparison of a large number of oxido-reductase
structures, Wierenga et al. [30] concluded that NADP(H)
and NAD(H) bind similarly to the 13ap-fold. Because
173-HSD also binds NAD(H) [14], the position of the
2'-phosphate may be occupied by another ion, as has
been proposed for glutathione reductase [31].
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Fig. 1. (a) Stereo ribbon diagram of a
monomer of human estrogenic 171-
hydroxysteroid dehydrogenase (HSD).
The course of the polypeptide chain is
shown for residues 1-284. c-helices are
drawn as magenta coils, 3-strands as
blue arrows, and turns and loops as
green ropes. The side chains for
residues in the active site belonging to
the catalytic triad, Tyr1 55-Lys159-
Ser142, are shown in white. The view is
almost parallel to the central p-sheet.
(Figure- prepared using the program
SETOR [43].) (b) Folding topology of
strands (triangles) and helices (circles) in
17-HSD.
In the catalytic cleft (Fig. 6) the adenine-ribose end of
the modeled cofactor is surrounded by five segments of
the protein chain: residues Gly9-Serl 1 of the 3A to oB
turn, Arg37 from the PB to oC turn, residues
Asp65-Arg67 from the end of PC, residues Ala91-Leu93
of D, and Vall113 of otE. The 2'-phosphate oxygen
atoms form hydrogen bonds with the side-chain
hydroxyl of Serll, with main-chain amide groups and
with the side chain of Arg37. The nicotinamide-ribose
end of the cofactor is surrounded by Asn90,
Thrl4O-Ser142, Tyr155, Lys156 and Vall188-Met193.
The pro-S hydride face (B-face) of the nicotinamide ring
is directed towards the steroid-binding cleft, which is
lined by the conserved catalytic triad Tyrl55-Lysl59-
Ser142 on one side and the helix otG' on the other. It
has been shown that a steroid-like enzyme inhibitor
binds competitively at the analogous catalytic site in
3o,203-HSD and forms a hydrogen bond with the cat-
alytic tyrosine hydroxyl [32,33].
Substrate recognition and the transition state
A 1713-estradiol molecule has been modeled into the
active site to mimic the transition state of the estrone to
17[-estradiol reaction (Fig. 7a,b). In the proposed transi-
tion state, the pro-S hydride from the nicotinamide is
transferred to the ot-face of the steroid at the C17 atom,
whereas the keto oxygen at C17 forms a strong hydrogen
bond (2-2.5 A) with the hydroxyl of Tyrl55. The
hydride transfer could occur over a short distance of -2 A
(2.7 A between C4 of the nicotinamide ring and C17 of
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Fig. 2. A (2 Fobs-Fcalc)) electron-density map of the helix aG', in
stereo, calculated with the refined model which is shown in stan-
dard atom colors (symmetry-related atoms are shown in white).
Atoms in the neighboring regions have been removed for clarity.
The map is contoured at 1.2u. (Figure prepared using the
program CHAIN [41 ].)
the steroid in the model shown). A proton-transfer
interaction between the 17-keto oxygen and the Tyr155
hydroxyl could be facilitated by the close proximity of
the protonated Lys159 side chain. Although no direct
interaction between Lys159 and Tyr155 is observed in
the crystal structure (Tyr155 OH...NC Lys159, 4.4 A),
the transition state (shown in Fig. 7b) might be arrived at
by a small conformational change. The Ser142 hydroxyl
could also donate a proton to Tyr155, either to stabilize
any oxyanion intermediate, or to replenish the missing
proton on Tyrl55 from the solvent network, or both.
One or more of these three side chains (Ser142, Tyr155,
Lys159) should then be undergoing dynamic exchange of
protons with solvent molecules. We found that the
Lys159 side chain, buried in the active-site cleft, is hydro-
gen bonded to a solvent water molecule. This is not sur-
prising, as a protonated and buried lysine is likely to be
solvated. However, the observation of a water molecule
bound to Lys159 may also indicate the participation of
this side chain in the proton-relay network.
A color-coded Connolly surface of the active-site cavity,
as it is observed in the crystal structure determination
(Fig. 8), shows that the 3-hydroxyl end of the A ring of
17[-estradiol has to fit into a relatively narrow cavity and
make specific binding interactions in order to attain a
suitable stereochemical orientation for catalysis to occur
at the C17 end of the molecule. The 3-hydroxyl oxygen
of the steroid molecule, as positioned in this model,
would be 3.4 A from N8 of the His221 side chain,
located on the oYG' helix (Fig. 7a). The side chains of a
few other residues, including Tyr218, Ser222, Val225,
Fig. 3. A ribbon diagram of 17P-HSD structure with the
substrate-binding domain, comprising helices aG", cG', oxH' and
ctH, highlighted in gold. The modeled substrate, 17-estradiol,
is shown in stick representation. (Figure prepared using the
program SETOR [43].)
Met279 and Val283 from helices otG' and oH, which
border the active site, are located within the steroid-
binding cavity. Therefore, the new domain composed of
helices otG", oLG', otH' and otH (gold colored in Fig. 3),
may determine recognition and selectivity of substrates
and influence the stereospecificity of the reaction. The
shape-recognition of the substrate at this end (i.e. the flat
aromatic A-ring of estrogens) is achieved through steric
interactions with atoms bordering the narrow cavity,
primarily from helices not found in the structures of
3a,20P3-HSD and DHPR.
A few cysteines, three histidines and a tyrosine residue, all
believed to be in the active site, were tagged with
bromoacetoxy steroid inhibitors in affinity-labeling
experiments [16-18,34,35]. An oxidized cofactor pro-
tected the essential lysine and a cysteine residue from
being labeled by trinitrobenzene sulfonate [19]. Our
structural results suggest that the labeled lysine was prob-
ably Lys159 (Fig. 6), which would be protected by
NADP+. Cys185, which binds Hg2 + producing the iso-
morphous heavy-atom derivative used here for structure
508 Structure 1995, Vol 3 No 5
Fig. 4. Stereo ribbon representation of
the dimer of human estrogenic 17p3-
HSD, which is the biochemically active
form of the enzyme. The two subunits
are related by a crystallographic two-
fold axis of symmetry. The interface
generated by this rotation axis, parallel
to the direction of view at the center of
the four-helix bundle (comprising the
two aE and two aF helices), is identical
to the Q-axis interface in bacterial
3a,201-HSD. (Figure prepared using the
program SETOR [43].)
solution (see the Materials and methods section), would
also have been protected from bromoacetoxy tagging by
NADP+. Two other cysteines are found in and around
the active-site cleft: Cys156 near the steroid-binding site
and CyslO near the cofactor site (Fig. 6). Helix oxG'
contains two other histidine residues, His210 and
His213, that are farther away from the active site than
His221. The labeled peptides isolated from human
placental and porcine testicular 173-HSDs in histidine-
labeling experiments are identical to each other in amino
acid sequence and correspond to the segment
Leu204-Lys223 of 1713-HSD, most of which belongs to
oxG'. His221 is the most likely candidate for having been
labeled, as clearly shown in Figure 7a. A recent site-
directed mutagenesis study [36] showed that Tyr155 and
His221 are essential for the activity of the enzyme.
Fig. 5. A stereodiagram of superimposed
Co chains of bacterial 3a,2013-HSD
(magenta) and human estrogenic
17,-HSD (cyan). The superposition was
achieved by least-squares fitting 20 Ca
atoms that are at similar positions in
both structures. The cofactor, NAD,
bound to 3a,20,-HSD is shown in yel-
low. (Figure prepared using the program
SETOR 143].)
Table 5. Distances (in A) between pairs of Ca atoms.
Ca pair Ca pair
171-HSD 3a,203-HSD 1 73-HSD 3a,201-HSD
Thr3 Lys7 0.6 (A) Leu126 ile123 0.9 (A)
lle7 Ilel 1 0.1 (A) Argl 36 Serl 33 0.4 (A)
Gly9 Glyl3 0.3 (A) Serl 42 Serl 39 0.8 (A)
Alal9 Ala23 0.8 (A) Glyl45 Gly142 0.5 (A)
Tyr33 Val34 0.4 (A) Asn152 Thr149 0.8 (A)
Asp65 Asp60 0.8 (A) Tyr155 Tyr152 0.9 (A)
Asp85 Asp82 0.8 (A) Lysl 59 Lysl56 0.1 (A)
Asn90 Asn87 0.8 (A) Leu169 Ala166 0.9 (A)
Vall 10 Val107 0.8 (A) Leu182 Serl79 0.5 (A)
Va1 15 Leull 12 0.7 (A) His189 Tyr186 0.9 (A)
The 20 Ca pairs used for least-squares superposition were selected
uniformly from structurally conserved residues along the polypeptide chain.
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Fig. 6. Close-up stereoview of the active
site of human estrogenic 1 71-HSD show-
ing the cofactor and the steroid-binding
clefts. The modeled NADP(H) and 17p3-
estradiol molecules are shown in brown
and green, respectively. Side chains of
the residues constituting the catalytic
triad, Tyr155-Lys159-Ser142, are shown
in red. The steroid molecule is positioned
relative to Tyr155 and the nicotinamide
ring of the cofactor in accordance with
the proposed transition state of estrone to
estradiol interconversion. Also shown (in
white) are residues that line the cofactor
and the steroid-binding clefts, namely
Cys10, Ser11, Asn90, Ala91, Va1113,
Met147, Leu149, Cys156, Cys185,
Metl 93, Tyr218, His221, Ser222, Val225,
Phe226, Leu262, Leu263, Met279 and
Val283. (Figure prepared using the pro-
gram SETOR [43].)
Fig. 7. (a) Stereoview of the atomic
model of the proposed transition state of
estrone to estradiol interconversion. All
atomic positions shown are obtained
from the present study, except those of
the cofactor and the steroid molecules
that were derived from modeling. The
3-face of the steroid is oriented towards
Tyr155 and the pro-S hydride from the
C4 atom of the nicotinamide ring
approaches close to C17 of 17[-estra-
diol. (Figure prepared using the program
CHAIN [41].) (b) The proposed mecha-
nism of estrone to estradiol interconver-
sion. Lys159 and Ser142 side chains
could also approach the Tyr155 hydroxyl
in the transition state (see text for expla-
nation). A few solvent water molecules
were located near the active-site cleft,
although none is within hydrogen-bond-
ing distance of the Tyr155 side-chain
hydroxyl group. One water molecule
was found in close interaction with the
buried Lysl 59 side chain.
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Fig. 8. A dotted Connolly surface of the
active-site cavity, drawn with a probe
radius of 1.35 A. Color coding as fol-
lows: carbon, green; oxygen, red; nitro-
gen, blue; sulfur, yellow. Modeled
17p-estradiol and part of the NADP+
molecule are also shown. (Figure pre-
pared using the program CHAIN [41].)
Fig. 9. Helices (a) cG' and (b) aH
viewed along the helical axis. The side
chains are color coded to illustrate their
amphiphilicity, as follows: green, hydro-
phobic; red, charged; and magenta,
residues having a proton-donating func-
tional group. (Figure prepared using the
program SETOR [43].)
Possible membrane association
The amphiphilic nature of two of the helices that form
one end of the substrate-binding pocket, oxG' and xH, is
illustrated in Figure 9. A third, shorter, helix in that
region, otH', is primarily hydrophobic. Many amphiphilic
helices are postulated to bind or insert into lipid bilayers
[37]. These three helices, aoG', caH and oH', are roughly
coplanar. The hydrophobic surface thus generated con-
tains residues Phe215, Tyr218, Leu219, Val225, Phe226,
Leu260, Pro261, Leu262, Leu263, Met265, Tyr275,
Val276, Ala278, Met279, His280, Val283 and Phe284.
Most of this hydrophobic surface is directed towards the
steroid-binding cleft. The hydrophilic surface of the
opposite face of the helix cluster contains residues
Thr213, Arg214, Tyr216, Gln217, Gln224, Lys223,
Arg227, Arg264, Arg266, Ser273, Asn274, Thr277 and
Arg281, all of which are capable of interacting with the
phosphate-rich surface of the phospholipid bilayer. From
the topological distribution of these helices, it appears
that the polar surface could interact with the bilayer sur-
face of the membrane, whereas some of the hydrophobic
side chains might penetrate deeper into the bilayer. How-
ever, this polar surface also contains two glutamic acid
side chains (228 and 282) which are not likely to interact
with the bilayer surface. The Glu282 side chain forms a
salt bridge with the His221 side chain in the crystal struc-
ture. The His221 side chain, postulated above to form a
hydrogen bond with the 3-hydroxyl group of the sub-
strate as a mode of recognition, is roughly intermediate in
position between the two surfaces.
It is possible that molecules of estrogenic 17-HSD asso-
ciate with a membrane through interaction of one or
more of the helices otG', aH' and axH with the lipid
bilayer. Because these helices are distant from both the
Q-axis and the P-axis interface, catalytically active dimers
or tetramers could form without disturbing the potential
for membrane association. Interestingly, the electron
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density for the C terminus, which is rich in alanine,
glycine, proline and other hydrophobic residues, is ill
defined beyond the end of otH at position 285. A stable
conformation of the ill defined C-terminal residues may
arise as a result of hydrophobic interaction within the
membrane.
Other isozymes of 1 73-HSD
In addition to the type I 1713-HSD that is the subject of
this present study, two 17-HSDs with different substrate
specificities have been characterized [38]: the type II
enzyme (capable of testosterone to androstenedione as
well as estrone to estradiol interconversion) and the type
III enzyme (specific for testosterone to androstenedione
interconversion) have 80 and 46 additional N-terminal
residues, respectively, relative to the type I enzyme (387
and 310 total amino acid residues, respectively). Because
these N-terminal insertions are hydrophobic in nature
they may enhance membrane association of type II and
type III enzymes. However, sequence comparison sug-
gests that the overall structures of the two forms of
17P-HSD are quite similar to that of type I. Differing
substrate specificities may arise from sequence differences
in the region 192-228 (of type I), a significant portion of
which is the helix aG', which constitutes the proposed
substrate-recognition region of the active site. The
equivalent substrate-recognition regions in types II and
III incorporate residues 269-313 and 235-261, respec-
tively. Pairwise comparisons between the three proteins
reveal an overall sequence identity of 23% [38], but the
identity in the substrate-recognition region is only -10%,
which is nearly random. Moreover, residue His221,
which is proposed to be critical for substrate recognition
by 17f-HSD type I, is not conserved in isozyme types II
and III. Despite the structural similarity in the overall
fold, differences in the active sites of the various short-
chain steroid dehydrogenases must account for substrate
specificity and should permit the design of specific
inhibitors.
been proposed. Site-directed mutagenesis studies
have confirmed that the conserved tyrosine and
lysine residues are essential for enzyme function.
The present investigation constitutes the first
X-ray structure determination of a mammalian
steroidogenic enzyme. Our results demonstrate
that despite only about 15% sequence identity and
the presence of two major insertions and addi-
tional residues at the C terminus, 1713-HSD has
the same overall fold as bacterial 3ot,20-HSD and
mammalian DHPR. The additional residues in
1701-HSD form two helix-turn-helix motifs, and
these constitute a 'substrate-recognition domain'
bordering the active site at the end of the
steroid-binding cavity opposite the cofactor-bind-
ing site and the catalytic residues. The apparent
amphiphilic nature of the additional helices and
their topological location are consistent with the
observed association of the enzyme with microso-
mal membranes. Modeling with 1713-estradiol at
the active site suggests that the 3-hydroxyl end of
the substrate, which is at the end of the molecule
opposite to where the oxido-reductive reactions
occur, fits into a cavity in this domain while form-
ing a specific hydrogen bond with a histidine side
chain. Comparable substrate-recognition features
are not present in the active site of the bacterial
enzyme, allowing it to process a greater range of
substrates. The proposed transition state of the
enzyme is consistent with the relative locations of
the recognition histidine (a histidine side chain
that makes a specific hydrogen bond with the non-
reactive 3-hydroxyl end of the substrate) and the
catalytic Tyr-Ser-Lys triad in the active site. The
model of the active site of 171-HSD derived from
the present structure analysis provides a template
for the design of specific inhibitors as drugs for
breast cancer therapy.
Biological implications
Human estrogenic 17p3-hydroxysteroid dehydro-
genase (type I 17P-HSD) is responsible for the last
step of the biosynthesis of 173-estradiol, the most
potent naturally occurring human estrogen and a
potent stimulator of breast cancer. 173-HSD is a
member of a superfamily of oxido-reductases,
known as short-chain dehydrogenases, that also
includes bacterial 3a,20P-HSD, human renal
11P3-HSD, human placental 15-hydroxyprosta-
glandin dehydrogenase, rat liver dihydropteridine
reductase (DHPR) and Drosophila alcohol dehy-
drogenase. X-ray structure analyses of DHPR and
of bacterial 3a,20P-HSD (in the presence of its
NAD + cofactor and an inhibitor derived from
licorice) have identified the basic fold of this class
of enzymes and the location of cofactor and sub-
strate-binding sites. A catalytic mechanism involv-
ing an invariant Tyr-X-X-X-Lys sequence has
Materials and methods
Data collection
Human placental 173-HSD was crystallized as described [14].
The space group is C2 and the unit cell parameters are
a=123.56 A, b=45.()5 A, c=61.33 A, 3=99.02° . The data col-
lection was carried out on a Rigaku R-AXIS IIc image plate
area detector receiving X-rays from a Rigaku rotating anode,
and processed with R-AXIS data processing program package
(version 3.40). Three native data sets were collected, two with
placental protein crystals and one with crystals prepared from
recombinant protein. Three data sets were collected for a mer-
cury derivative, one set from each of three crystals soaked with
a solution of HgCl2. The placental enzyme crystals were used
for heavy-atom soaking. All data sets were collected at ambient
temperature. Table 1 summarizes the data collection statistics.
Structure solution and refinement
The structure of 173-HSD was determined using a combina-
tion of isomorphous heavy-atom methods and molecular
replacement techniques. The bacterial 3,203-HSD structure
was used for rotation and translation function searches. The
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program package X-PLOR [39] was used for molecular
replacement searches and also for the Patterson correlation
refinement of the rotation function results. Because of low
sequence identity (-15%) between 3t,203-HSD and
1713-HSD, potential molecular replacement solutions were
interpreted with caution. Several potential solutions were
selected, including the one that generated the predicted four-
helix bundle interface by the crystallographic two-fold rota-
tion. The initial phase sets from these solutions were used to
calculate difference Fourier maps with derivative and native
amplitudes. Only the phases from the correct molecular
replacement solution exhibited a large peak at the major
heavy-atom binding site, independently determined by the
difference Patterson method. Furthermore, this peak was
located close to the side chain corresponding to Cys187 in
17-HSD. By this cross-phasing technique, the correct chiral-
ity of the heavy-atom and the common origin choice between
the two phase sets were also determined. The heavy atom
positions were refined with HEAVY [40]. The single isomor-
phous replacement (SIR) phase calculation, phase combination
with the model phases and solvent flattening were carried out
using the PHASES package (W Furey and S Swaminathan,
Abstract PA33, Vol. 18, p. 73, American Crystallographic
Association Meeting, New Orleans, July, 1990). Summaries of
SIR phasing and phase combination statistics are provided in
Tables 2 and 3, respectively.
The initial model of 1713-HSD was built into a phase-com-
bined solvent-flattened map at 3.20 A resolution. Model build-
ing was performed on a SGI Elan workstation using CHAIN, a
modified version of FRODO [41]. The model was refined
with the X-PLOR package. The new phases were calculated
and combined with the SIR phases, and new annealed omit
maps were calculated for the problem regions. Corrections to
the model were made using these omit maps. The resolution of
the model was also gradually extended to 2.20 A, as the correc-
tions became fewer and completely new areas of the molecule
began to emerge in the electron-density maps. This process of
correcting the existing model, refinement of the model and
calculation of the new maps continued for many cycles. The
final model was largely error-free. The geometry and stereo-
chemistry of the model were checked with the PROCHECK
package [42]. A modest number of well defined water oxygens
have been modeled as bound, first-shell, solvent molecules.
The recombinant enzyme structure was refined using the par-
tially refined coordinates of the placental 17P-HSD. The
refinement summary is provided in Table 4.
Atomic coordinates have been deposited with the Brookhaven
Protein Data Bank.
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